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VEGF blockade damages brain vessels
A factor that promotes blood vessel growth keeps two types of brain cells 
alive, say Maharaj et al. (page 491). Their findings might explain why 
anticancer drugs that block this factor cause neurological side effects.
The drug target in question—vascular endothelial growth factor (VEGF)—
binds to receptors on blood vessel endothelial cells. A localized increase in 
VEGF, which is produced by underlying epithelial cells and other neighbor-
ing cells, promotes vessel growth in developing organs and injured tissues.
Lower levels of VEGF might also be necessary for the survival of 
endothelial cells, which become apoptotic when cultured in the absence 
of VEGF. VEGF-blocking drugs that limit tumor growth by inhibiting 
the tumors’ blood supply can cause seizures and brain swelling in some 
cancer patients. To find out whether these symptoms stem from the 
destruction of brain blood vessels, Maharaj et al. examined the brains of 
mice that had been engineered to express high levels of proteins that 
block VEGF and TGFβ—a cytokine that stimulates VEGF production.
Besides damage to brain endothelia, the mice developed brain lesions due 
to a breakdown of the barrier that pre-
vents cerebral spinal fluid from seeping 
into the brain. The specialized type of 
epithelial cells that make up this barrier 
expressed VEGF receptors and became 
apoptotic when VEGF was systemically 
blocked. Why brain complications only 
occur in a subset of cancer patients on 
anti-VEGF therapy is unknown. 
Averting danger from 
within
On page 451, Turer et al. find that loss of a 
single protein turns symbiotic bacteria into killers.
Helpful bacteria in the gut protect them-
selves by inducing the gut epithelia and local 
immune cells to secrete tissue repair factors 
and low, protective levels of cytokines and 
heat-shock proteins. This noninflammatory 
response is triggered by the binding of bac-
terial components to Toll-like receptors (TLRs). 
It has been assumed that these bacteria are 
helpful rather than harmful because the re-
sulting TLR signals are less potent than those 
triggered by foreign pathogens.
Turer et al. now show, however, that 
TLR signals triggered by symbiotic microbes 
are potentially lethal unless they are held in 
check. The team had previously found that 
mice lacking an antiinflammatory protein 
called A20 died from inflammation-related 
complications even in the absence of infec-
tion. They now find that this deadly inflam-
mation is triggered by ligands from the host’s 
own symbiotic bacteria.
Depleting the resident gut bacteria using 
antibiotics rescued the mice, as did knock-
ing out the TLR adaptor protein MyD88. 
Protection was less effective, however, if 
MyD88 was lost only from immune cells, 
suggesting that A20’s inhibitory effect pri-
marily acts in nonimmune cells—possibly in 
gut epithelial cells. The team is now investi-
gating whether A20 is required for cells to 
differentiate between pathogenic and pro-
tective TLR signals. 
Long-lasting Toll suppression
A study by Didierlaurent et al. (page 323) explains why fighting the flu 
makes us vulnerable to bacterial infections in the following months. 
A clampdown of innate immune receptors in the lung might leave the door 
open to opportunistic bacteria.
The team previously showed that mice that had just recovered from the flu 
had a weak inflammatory response that made them more susceptible to other 
pathogens over the next six months. The group now finds that post-flu 
inflammation in these mice is tempered by a dampened innate immune system.
The innate system usually responds to ligands that activate Toll-like receptors 
(TLRs). But in mice recovering from the flu, these ligands did not activate 
TLRs on lung macrophages. The cells therefore did not produce the chemokines 
necessary to attract neutrophils—the main instigators of lung inflammation.
Although the blunted TLR response might protect the lungs against 
inflammation-induced damage, it made them vulnerable to bacterial 
infection. After beating influenza, the mice were killed by pneumonia-
causing bacteria that are normally held at bay in the airways.
Influenza and other respiratory viruses are not known to encode TLR-
suppressing proteins. This suppression may thus represent the lung’s attempts to 
protect itself from damaging levels of inflammation. The authors suspect that 
the lungs might suppress TLR expression in response to any insult that causes a 
massive inflammatory response, including pathogens, injury, or environmental 
allergens. Their theory is bolstered by the fact that another respiratory pathogen, 
respiratory syncytial virus, also suppressed macrophage TLR signaling. 
Inflammation-related weight loss caused by symbiotic 
bacteria in A20-deficient mice (middle) is rescued 
by loss of MyD88 (right).
Mice that express high levels of 
VEGF-blocking molecules develop 
brain lesions (arrows).